Arteriosclerosis Obliterans
10
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
Arterial Calcification in the Diabetes
A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)
Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages
Sufficient Treatment of Peripheral Intervention by Cilostazol
TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation